FindTrial
Sign In

RANDOMISED, CONTROLLED STUDY WITH A BLINDED END-POINT TO EVALUATE BY MEANS OF 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING THE ANTIHYPERTENSIVE ACTIVITY OF OLMESARTAN 20 MG IN COMPARISON WITH THAT OF VALSARTAN 160 MG, AND THEIR COMBINATION WITH HYDROCHLOROTIAZIDE IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION WITH ANOTHER CARDIOVASCULAR RISK FACTOR..

RANDOMISED, CONTROLLED STUDY WITH A BLINDED END-POINT TO EVALUATE BY MEANS OF 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING THE ANTIHYPERTENSIVE ACTIVITY OF OLMESARTAN 20 MG IN COMPARISON WITH THAT OF VALSARTAN 160 MG, AND THEIR COMBINATION WITH HYDROCHLOROTIAZIDE IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION WITH ANOTHER CARDIOVASCULAR RISK FACTOR..

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-004380-32-IT
Enrollment
Unknown
Registered
2007-01-19
Start date
2005-09-15
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension MedDRA version: 9.1 Level: LLT Classification code 10015488 Term: Essential hypertension

Interventions

Trade Name: OLMETEC*28CPR RIV 20MG Pharmaceutical Form: Tablet INN or Proposed INN: Olmesartan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Trade Name: TAR

Sponsors

UNIVERSITA DEGLI STUDI DI PAVIA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026